Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Cytokinetics (CYTK) announced that AMBER-HFpEF is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, ...

In October 2023, it signed an agreement with Diakonos Oncology to develop a cell therapy, DOC1021, to treat glioblastoma ...

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome ...

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive interim data ...

As part of our Masterclass series, GP specialist in diabetes Dr Elizabeth Martin explains the key points in prevention, diagnosis and management of diabetes in general practice. This series showcases ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Cedars-Sinai shared the story of a Hollywood writer who kept his appointment for mitral valve surgery right after escaping ...

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

The message is that an early decrease in eGFR with finerenone should not lead to stopping the medication, say HF experts.